tiprankstipranks
Fusion Antibodies Plc (GB:FAB)
LSE:FAB
UK Market

Fusion Antibodies Plc (FAB) Income Statement

3 Followers

Fusion Antibodies Plc Income Statement

Last quarter (Q2 2023), Fusion Antibodies Plc's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Fusion Antibodies Plc's net income was £―. See Fusion Antibodies Plc’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 23Mar 22Mar 21Mar 20Mar 19
Total Revenue
-£ 2.90M£ 4.80M£ 4.17M£ 3.90M£ 2.18M
Cost of Revenue
-£ 2.33M£ 2.33M£ 2.14M£ 2.12M£ 1.38M
Gross Profit
-£ 574.00K£ 2.47M£ 2.02M£ 1.77M£ 804.00K
Operating Expense
-£ 3.48M£ 3.81M£ 3.27M£ 2.83M£ 2.31M
Operating Income
-£ -2.90M£ -1.35M£ -1.25M£ -1.06M£ -1.51M
Net Non Operating Interest Income Expense
-£ -1.00K£ -8.00K£ 15.00K£ -14.00K£ 9.00K
Other Income Expense
-£ -11.00K----
Pretax Income
-£ -2.86M£ -1.33M£ -1.26M£ -1.07M£ -1.50M
Tax Provision
-£ -263.00K£ -133.00K£ 1.64M£ -376.00K£ -235.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -2.60M£ -1.20M£ -2.90M£ -697.00K£ -1.26M
Basic EPS
-£ -0.10£ -0.05£ -0.11£ -0.03£ -0.06
Diluted EPS
-£ -0.10£ -0.05£ -0.11£ -0.03£ -0.06
Basic Average Shares
-£ 26.01M£ 25.95M£ 25.46M£ 22.09M£ 22.09M
Diluted Average Shares
-£ 26.01M£ 25.95M£ 25.61M£ 22.09M£ 22.09M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----£ 0.00£ 75.00K
Total Expenses
-£ 5.81M-£ -5.41M£ 4.95M£ 3.69M
Net Income From Continuing And Discontinued Operation
-£ -2.60M£ -1.20M£ -2.90M£ -697.00K£ -1.26M
Normalized Income
-£ -3.12M£ -1.47M£ -1.02M£ -697.00K£ -1.26M
Interest Expense
----£ 20.00K£ 4.00K
EBIT
-£ -2.85M£ -1.32M£ -1.25M£ -1.05M£ -1.50M
EBITDA
-£ -2.48M£ -573.00K£ -1.25M£ -431.00K£ -1.06M
Currency in GBP

Fusion Antibodies Plc Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis